Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Founded in 2015, Valera Health combines digital technology and data science with a human touch to deliver in-class clinical services to patients with mild to severe mental health conditions including depression to schizophrenia. With a focus on outcomes and servicing hard-to-reach populations, Valera Health is redefining high-performing mental healthcare.
Clever Care Health Plan, Inc. provides healthcare insurance plans to members that connect the benefits of Eastern and Western medicine. It offers plans for acupuncture, herbal remedies, and exercises, such as tai chi and qi gong; and treatments, including cupping and moxibustion. The company sells its products through brokers and sales agents. Clever Care Health Plan, Inc. was incorporated in 2018 and is headquartered in Westminster, California with an additional office in Arcadia, California.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
Upward Health is a home-based medical group that specializes in providing care to people with complex needs. It provides insurers with two primary benefits: exceptional care for high-risk, high-need, high-cost members, resulting in high-quality outcomes, and lower costs for providing care to those members. These benefits are provided by the company through hands-on, holistic care for the members.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Founded in 2015, Valera Health combines digital technology and data science with a human touch to deliver in-class clinical services to patients with mild to severe mental health conditions including depression to schizophrenia. With a focus on outcomes and servicing hard-to-reach populations, Valera Health is redefining high-performing mental healthcare.
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Willow is a female technology company that develops an in-bra wearable breast pump, replacement parts, breastfeeding essentials, pumping bras, cases and bags, breastfeeding essentials, and more.
ControlRad is developing innovative solutions that dramatically reduce the lifetime risk of radiation exposure from fixed and mobile C-arm procedures for patients and healthcare professionals, without compromising on image quality and workflow. ControlRad uses two interfaces to its add-on solution to C-arms, an eye tracker and a tablet.
RxWare is a SaaS company that enables pharmaceutical drug manufacturers to simplify patients' paths to therapy by connecting the siloed patient journey. To improve patient resource utilization and therapy outcomes, the company's Patient Gateway supports a variety of existing patient services and organizations, including ePrescribing systems, Hubs, specialty pharmacies, affordability solutions, system integrators, and nursing vendors. RxWare, which focuses on out-of-the-box connectivity, enables pharmaceutical brands to easily transform complex patient journeys into simple patient experiences. It provides a vendor-neutral digital infrastructure for drug manufacturers to streamline, accelerate, and optimize the entire patient journey. RxWare was founded in 2013.
ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California.
Science Exchange, Inc. operates an online marketplace for scientific services to collaborate with academic and government laboratories. Its platform assists researchers in searching scientific services from the U.S. research institutions; and researchers to compare service pricing, filter through quality testimonials, and pay for the service. The company also provides an enterprise dynamic report tool that enables pharma and biotech companies to perform real-time tracking of key performance indicators related to their outsourced R&D investments. Science Exchange, Inc., formerly known as theBench, Inc., was founded in 2011 and is based in Palo Alto, California.
Science Exchange Marketplace improves R&D productivity by automating many collaborative tasks between buyers and providers, such as obtaining quotes, managing projects, and processing payments, all with rigorous data security and regulatory compliance embedded throughout.
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
SubjectWell is the risk-free clinical trials marketplace for patient recruitment
andros is an NCQA-certified Credentials Verification Organization and technology-enabled provider network management solutions company. The credentialing segment of the business combines software and services to help payers and provider organizations to eliminate compliance risk, streamline operations and manage their providers better. The Network Development segment of the business utilizes proprietary data sets, technology and subject matter expertise to build and manage provider networks that control costs, ensure compliance and deliver value for local, regional and national health plans.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.
MC10, Inc. extends human capabilities through virtually invisible and conformal electronics. They reshape rigid, conventional electronics into thin, flexible devices that can stretch, bend and twist seamlessly with their bodies and the natural world. It combines breakthrough technology with innovative engineering to develop products that advance the quality of life. The company's end-to-end system designed for In-Home and In-Clinic Study Execution. Its proprietary BioStamp system wearable health tech creates comfortable, discreet sensors that can be applied anywhere on the body for targeted data collection. With location-specific sensing capabilities, BioStamp sensors are able to retrieve real-world data about muscle activation and movement.
Cureatr develops a cloud-based medication management software to optimize patient care. It offers healthcare management services that focus on post-discharge medication reconciliation and other medical services triggered by real-time events.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Cartiva is a private, venture capital-backed company that was spun out from Carticept Medical in December 2011. Cartiva is dedicated to improving the quality of life for patients with osteoarthritis or cartilage damage through the development of novel therapies. Cartiva’s mission is to develop and market products to help physicians treat osteoarthritis and cartilage injuries and the related pain more effectively. The company's management team, the board of directors, and medical advisors are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval, and successful commercialization. Cartiva is located in Alpharetta, Georgia.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
Science Exchange Marketplace improves R&D productivity by automating many collaborative tasks between buyers and providers, such as obtaining quotes, managing projects, and processing payments, all with rigorous data security and regulatory compliance embedded throughout.
DOTS (Detection On The Spot) is changing the field of point of care detection with a revolutionary diagnostics platform with consumer and industrial applications. For the millions of consumers with food allergies, DOTS is creating a food allergen detection system to test food on the spot, provide more information for better decisions, and improve overall quality of life .
GlySens Incorporated is a privately held corporation devoted to developing the world’s first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes. The GlySens fully implanted sensor—demonstrated up to 18 month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGMTM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. The GlySens ICGM system is currently undergoing clinical evaluation; initial human implant trials have been completed, and preparations for additional human trials are underway.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Cureatr develops a cloud-based medication management software to optimize patient care. It offers healthcare management services that focus on post-discharge medication reconciliation and other medical services triggered by real-time events.
Coravin offers a proprietary wine access technology that does not disturb a wine's aging process even after the cork is removed. The company's technology allows them to pour and enjoy fine wines without disturbing the natural aging process- or the process to commit to the whole bottle. Its first product, the Coravin Wine Preservation Opener, pours wine without removing the cork from the bottle. Coravin was founded in 2011 and is headquartered in Bedford, Massachusetts, United States.
ClarVista Medical is a developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing, ClarVista was spun out from Prospex Medical, a medical device incubator, to pursue the development of the HARMONI™ IOL. Between 2012 and 2014, the company developed the first generation HARMONI™ system, conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system, conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.
Cartiva is a private, venture capital-backed company that was spun out from Carticept Medical in December 2011. Cartiva is dedicated to improving the quality of life for patients with osteoarthritis or cartilage damage through the development of novel therapies. Cartiva’s mission is to develop and market products to help physicians treat osteoarthritis and cartilage injuries and the related pain more effectively. The company's management team, the board of directors, and medical advisors are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval, and successful commercialization. Cartiva is located in Alpharetta, Georgia.
Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.
RxWare is a SaaS company that enables pharmaceutical drug manufacturers to simplify patients' paths to therapy by connecting the siloed patient journey. To improve patient resource utilization and therapy outcomes, the company's Patient Gateway supports a variety of existing patient services and organizations, including ePrescribing systems, Hubs, specialty pharmacies, affordability solutions, system integrators, and nursing vendors. RxWare, which focuses on out-of-the-box connectivity, enables pharmaceutical brands to easily transform complex patient journeys into simple patient experiences. It provides a vendor-neutral digital infrastructure for drug manufacturers to streamline, accelerate, and optimize the entire patient journey. RxWare was founded in 2013.
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
Welldoc develops technology solutions to support chronic disease management. They work with leaders across the healthcare, life science, and medical device industries to ensure the solutions they develop scale and integrate into their existing workflows and systems. The Welldoc platform offers support for multiple chronic conditions, ecosystem solutions, and artificial intelligence.
MC10, Inc. extends human capabilities through virtually invisible and conformal electronics. They reshape rigid, conventional electronics into thin, flexible devices that can stretch, bend and twist seamlessly with their bodies and the natural world. It combines breakthrough technology with innovative engineering to develop products that advance the quality of life. The company's end-to-end system designed for In-Home and In-Clinic Study Execution. Its proprietary BioStamp system wearable health tech creates comfortable, discreet sensors that can be applied anywhere on the body for targeted data collection. With location-specific sensing capabilities, BioStamp sensors are able to retrieve real-world data about muscle activation and movement.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
MC10, Inc. extends human capabilities through virtually invisible and conformal electronics. They reshape rigid, conventional electronics into thin, flexible devices that can stretch, bend and twist seamlessly with their bodies and the natural world. It combines breakthrough technology with innovative engineering to develop products that advance the quality of life. The company's end-to-end system designed for In-Home and In-Clinic Study Execution. Its proprietary BioStamp system wearable health tech creates comfortable, discreet sensors that can be applied anywhere on the body for targeted data collection. With location-specific sensing capabilities, BioStamp sensors are able to retrieve real-world data about muscle activation and movement.
Transactis transforms traditional paper billing and payment processing by enabling businesses of all sizes to replace paper bills, statements, invoices, payments and documents with more efficient digital alternatives. Transactis goes to market exclusively with resellers—financial institutions, technology companies, printers and business process outsourcers—to provide their customers with secure, configurable, white-label, industry-leading SaaS solutions. More than a technology provider to resellers, Transactis is a full-service business partner, delivering a broad and deep suite of sales, marketing, technical and operational support, empowering resellers to more successfully serve their clients. Transactis meets the strictest regulatory and compliance requirements including HIPAA, SSAE 16, PCI Level 1, and SOC 2. Transactis’ investors include ff Venture Capital, MacAndrews & Forbes, Metamorphic Ventures, Safeguard Scientifics, StarVest Partners, Capital One, Fifth Third Bank, PNC, TD Bank and Wells Fargo.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.